Romosozumab outperforms teriparatide and denosumab in bone strength
Published: September 15th 2025 | Updated: September 16th 2025Recent work presented at the 2025 annual meeting of American Society of Bone & Mineral Research found that romosozumab significantly outperformed teriparatide and denosumab in improving hip and spine bone strength.